Earl Douglas General Counsel, Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment…
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024…
Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs…
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered TestingLaunch of VELDONA® Pet Provides New Revenue Stream…
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on…
ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…
Conference Call/Webcast Scheduled for Today at 4:30 PM ETSTONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA…
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised…
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipelineSAN DIEGO,…